Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

NCT05381506 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

77

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: Orelabrutinib and Gemox

Sponsor

Sun Yat-sen University